Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies (Q38580545)

4 September 2017

title

Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies (English)

1 reference

4 September 2017

1 reference

1 reference

1 reference

Rebecca Karp Leaf

1

1 reference

4 September 2017

Hearn Jay Cho

series ordinal

2

1 reference

4 September 2017

David Avigan

series ordinal

3

1 reference

4 September 2017

publication date

4 September 2015

1 reference

Current hematologic malignancy reports

4 September 2017

published in

1 reference

4 September 2017

volume

10

1 reference

4 September 2017

issue

4

1 reference

4 September 2017

page(s)

395-404

1 reference

Lenalidomide in multiple myeloma

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Proteasome inhibitors in the treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Targeting multiple-myeloma-induced immune dysfunction to improve immunotherapy outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

FOXP3 and CTLA4 overexpression in multiple myeloma bone marrow as a sign of accumulation of CD4(+) T regulatory cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Enhancement of clonogenicity of human multiple myeloma by dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Pathogenesis beyond the cancer clone(s) in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Myeloid-derived suppressor cells as regulators of the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Multiple myeloma induces Mcl-1 expression and survival of myeloid-derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Microenvironmental regulation of tumor progression and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Ex vivo induction of multiple myeloma–specific cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Daratumumab granted breakthrough drug status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Molecular cloning of CS1, a novel human natural killer cell receptor belonging to the CD2 subset of the immunoglobulin superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Cyclic ADP-ribose and nicotinic acid adenine dinucleotide phosphate (NAADP) as messengers for calcium mobilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Biological functions of ecto-enzymes in regulating extracellular adenosine levels in neoplastic and inflammatory disease states

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

A CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Allogeneic hematopoietic cell transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

A comparison of allografting with autografting for newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Myeloma proteins as tumor-specific transplantation antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Targeting heat shock proteins for immunotherapy in multiple myeloma: generation of myeloma-specific CTLs using dendritic cells pulsed with tumor-derived gp96.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Phage idiotype vaccination: first phase I/II clinical trial in patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Association of antigen-specific T-cell responses with antigen expression and immunoparalysis in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Cancer-testis antigen 7 expression and immune responses following allogeneic stem cell transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Induction of multiple myeloma-specific cytotoxic T lymphocyte stimulation by dendritic cell pulsing with purified and optimized myeloma cell lysates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Dendritic cell immunotherapy for cancer: application to low-grade lymphoma and multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Idiotype-pulsed antigen-presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

A novel immunogenic CS1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

A multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell-depleted hematopoietic stem cell transplantation and donor lymphocyte infusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Cancer/testis antigens: an expanding family of targets for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Dendritic cells: development, function and potential use for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Mechanisms and functional significance of tumour-induced dendritic-cell defects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Enhanced cross-priming of naive CD8+ T cells by dendritic cells treated by the IMiDs® immunomodulatory compounds lenalidomide and pomalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

CTLA-4: new insights into its biological function and use in tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Immunologic correlates of the abscopal effect in a patient with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Immune checkpoint blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Gastrointestinal graft-versus-host disease in recipients of autologous hematopoietic stem cells: incidence, risk factors, and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Managing cytokine release syndrome associated with novel T cell-engaging therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0283-0

Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning

21 January 2018

1 reference

12 December 2020

Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma

1 reference

12 December 2020

CD8+ T cells specific for cancer germline gene antigens are found in many patients with multiple myeloma, and their frequency correlates with disease burden

1 reference

12 December 2020

Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation

1 reference

12 December 2020

Immunotherapy with chimeric antigen receptors for multiple myeloma

1 reference

12 December 2020

Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients

1 reference

12 December 2020

Induction of leukemia-specific cytotoxic response by cross-presentation of late-apoptotic leukemic blasts by autologous dendritic cells of nonleukemic origin.

1 reference

12 December 2020

Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study.

1 reference

12 December 2020

Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors

1 reference

12 December 2020

Donor lymphocyte infusion enhances remission status in patients with persistent disease after allografting for multiple myeloma

1 reference

12 December 2020

Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients.

1 reference

12 December 2020

Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies

1 reference

12 December 2020

Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome

1 reference

12 December 2020

Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma

1 reference

12 December 2020

A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma

1 reference

12 December 2020

Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial

1 reference

12 December 2020

Expression of MUC1 on myeloma cells and induction of HLA-unrestricted CTL against MUC1 from a multiple myeloma patient

1 reference

12 December 2020

Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses

1 reference

12 December 2020

Signal transduction by the T cell antigen receptor

1 reference

12 December 2020

Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant

1 reference

12 December 2020

MAGE-C1/CT7 is the dominant cancer-testis antigen targeted by humoral immune responses in patients with multiple myeloma

1 reference

12 December 2020

Genes encoding tumor-specific antigens are expressed in human myeloma cells

1 reference

12 December 2020

Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy

1 reference

12 December 2020

10.1007/S11899-015-0283-0

Identifiers

DOI

1 reference

Dimensions Publication ID

4 September 2017

1022279516

0 references

1 reference